Q-omics provides the consensus-scored MIR6851 profile across patient tissues and cancer cell-line models. MIR6851 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR6851 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MIR6851 RNA expression shows 5,741 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight ACC, COAD, and KIRC as cancer lineages where MIR6851 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6851 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6851 survival associations across molecular data types. MIR6851 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6851 RNA expression–survival associations across cancer types. High MIR6851 expression shows unfavorable associations in ACC, TGCT, THCA, PRAD, MESO and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR6851 RNA expression.
This table summarizes MIR6851 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6851. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6851 shows higher tumor expression in COAD, LUAD, PRAD, STAD, HNSC and LIHC. The COAD box plot shows higher MIR6851 RNA expression in tumor versus normal tissue (log2 FC = +0.409, t-test p = .001).
This table shows molecular features associated with MIR6851 in patient tissues and cancer cell lines. In patient samples, MIR6851 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
